Novartis Seeks European Approval for Xolair as First-in-Class Treatment for Severe Allergic Asthma
BASEL, Switzerland, July 2 (ots/PRNewswire) - Novartis Pharma AG yesterday submitted its application for the European approval of Xolair(R) (omalizumab), a novel therapy which targets a root cause of allergic disease and offers an entirely new approach to the treatment of allergic asthma. The file, submitted to ...
mehr